Appointment of Anilkumar Mohanbhai Amreliya as Additional Director
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Novyra Pharmachem Limited (formerly Bansisons Tea Industries Limited) approved the appointment of Anilkumar Mohanbhai Amreliya (DIN: 11339148) as Additional Executive Director effective 6th February 2026, at a meeting held from 4:30 p.m. to 5:30 p.m. Amreliya brings over 25 years of experience in sales and marketing and currently serves on the boards of Vaidehi Healthcare Private Limited and Vaid Super Specialty Hospital Private Limited. He holds no shares or significant voting power in the company and is not debarred by SEBI or any other authority. The appointment is until the next Annual General Meeting, after which shareholder approval will be sought.
The new director's healthcare background aligns with the company's apparent strategic shift from tea to pharma/chemicals (evidenced by the name change to Novyra Pharmachem), which could be viewed positively by shareholders looking for growth in a new sector. This is a routine governance update and unlikely to cause immediate stock price movement, but it signals ongoing board restructuring to support the company's new business direction.